Skip to main content

Table 1 Baseline characteristics

From: Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study

  SLE (n = 59) Healthy controls (n = 65)
Female sex 55 (93 %) 45 (69 %)
Age, yr 44 ± 16 48 (14)
Caucasian 59 (100 %) 65 (100 %)
Disease duration, yr 7 ± 7  
SLICC/ACR Damage Index 0.8 ± 1.4  
SLEDAI-2 K 3.7 ± 3.5  
 cSLEDAI-2 K (only clinical SLEDAI-2 K items) 2.2 ± 3.0  
 SLEDAI-2 K ≥4 30 (53 %)  
 SLEDAI-2 K ≥6 19 (33 %)  
 Any SLEDAI-2 K clinical features 26 (45 %)  
 Neuropsychiatric featuresa 2 (3 %)  
 Vasculitisa 0 (0 %)  
 Arthritisa 10 (17 %)  
 Myositisa 0 (0 %)  
 Renal featuresa 8 (14 %)  
 Rasha 9 (15 %)  
 Alopeciaa 5 (9 %)  
 Mucosal ulcersa 0 (0 %)  
 Serositisa 1 (2 %)  
 Haematological featuresa 3 (5 %)  
 Fevera 0 (0 %)  
 Increased DNA bindinga 22 (38 %)  
 Low complementa 28 (48 %)  
Anti-nucleosome antibody–positive 25 (46 %)  
Oral glucocorticoids 35 (59 %)  
Immunosuppressants 15 (25 %)  
  1. ANA anti-nuclear antibodies, SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index 2000, anti-dsDNA anti–double-stranded DNA, SLICC/ACR Systemic Lupus International Collaborating Clinics/American College of Rheumatology, SLE systemic lupus erythematosus
  2. Data are presented as number and percentage or mean and standard deviation
  3. aAccording to SLEDAI-2 K definitions; renal, haematological, serositis and neuropsychiatric SLEDAI-2 K features were merged into one item (see Definitions section in text)